Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies


Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused By Ragweed Pollen




The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration

Study Status: Active, not recruiting


Condition Intervention Phase
Allergic Rhinitis Biological: Ragweed Allergenic Extract Immunotherapy
Biological: Ragweed allergenic extract
Phase 3

Verified by Greer Laboratories June, 2008

Sponsored by: Greer Laboratories
Information provided by: Greer Laboratories identifier: NCT00599872

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site